Purpose: WWOX (WW domain containing oxidoreductase) is a tumor suppressor gene that maps to the common fragile site FRA16D. We showed previously that WWOX is frequently altered in human lung and esophageal cancers. The purpose of this study was to delineate more precisely the role of WWOX in pancreatic carcinogenesis.
INTRODUCTION
Pancreatic cancer is one of the most common human cancers and carries a poor prognosis (1) . Although complete surgical resection is the only therapeutic option for a long-term survival, the 5-year survival rate with curative resection is Ͻ20% (2) . The precise molecular mechanisms of development and/or progression of pancreatic cancer remain unknown, although multiple genetic and epigenetic changes have been detected in pancreatic cancer. Therefore, additional elucidation of the molecular mechanisms involved in pancreatic cancer is urgently needed for more effective treatment.
The tumor suppressor gene FHIT spans the FRA3B fragile site, the most active common chromosome fragile site of the human genome, and abnormal FHIT transcripts have been detected in many human cancers, including pancreatic cancer (3) (4) (5) (6) . Additionally, our previous study demonstrated that FHIT overexpression enhanced the susceptibility of pancreatic cancer cells to exogenous inducers of apoptosis (7) . Recently, in the WWOX (WW domain containing oxidoreductase), a candidate tumor suppressor gene, chromosome 16q23.3-24.1 was isolated. This gene maps at the location of FRA16D, one of the most active common chromosomal fragile sites (8 -11) . The WWOX gene is similar to the FHIT gene in that both genes are Ͼ1 Mb and encompass very active common fragile sites, both genes show frequent allelic loss and/or loss of homozygous deletion region in several human cancers, and both frequently show aberrant transcripts (5, 10, 11) . Because increased risk of pancreatic cancer is associated with cigarette smoking and because the carcinogens present in tobacco smoke cause deletions at the FHIT/FRA3B loci (5, 6), we hypothesized that the WWOX gene may play a role in pancreatic cancer. In this report, we describe that WWOX is altered frequently in pancreatic cancer by genetic and/or epigenetic changes and is involved in pancreatic carcinogenesis. the 9 cell lines and from the 15 paired pancreatic tissues according to methods described previously (12) . RNA was extracted with the Trizol reagent (Invitrogen Life Technologies, Inc., Carlsbad, CA) per the manufacturer's recommendations.
Loss of Heterozygosity (LOH) Analysis. Allelic losses were analyzed using a PCR approach, with primers amplifying polymorphic microsatellites internal to WWOX at loci D16S3029, D16S3096, D16S504, and D16S518, as described elsewhere (13) . Briefly, the primer sequences were obtained from the Genome Database and primers were labeled using 5Ј-fluorescein phosphoramidite or 5Ј-tetrachlorofluorescein phosphoramidite for microsatellite loci, as described by Ishii et al. (14) . PCR was performed on 50 ng of DNA for each sample using the conditions described for the mutation search. PCR products were denatured in formamide for 5 min at 95°C and then loaded on a 6% denaturing gel on the Applied Biosystems 373 DNA sequencer. LOH was analyzed using the Applied Biosystems Prism Genescan and the Applied Biosystems PRISM GENETYPER ANALYSIS software (PerkinElmer/Applied Biosystems). Cases were defined as having LOH when an allele peak signal from tumor DNA was reduced by 50% compared with the normal counterpart.
Mutation Screening of the WWOX Gene. Nine pairs of primers for individual exon amplification and screening were used for PCR screening with genomic DNA. The primers for each exon are specified in GenBank (accession numbers AF325423-325432). The PCRs were performed with the same conditions as those described for the LOH analysis. The PCR products were purified using the QIAquick PCR purification kit (Qiagen, Inc., Valencia, CA), and sequencing reactions and analysis were performed using the Applied Biosystems Prism BigDye terminator reaction chemistry on a Perkin-Elmer Gene Amp PCR system 9600 and the Applied Biosystems Prism 377 DNA sequencing system (Applied Biosystems, Inc., Foster City, CA).
Nested Real-Time Reverse Transcription PCR Analysis of the WWOX Transcripts. cDNA was synthesized from 2 g of total RNA and real-time reverse transcription PCR was performed as described previously (13) . Glyceraldehyde-3-phosphate dehydrogenase amplification served as a control for cDNA quality. One l of cDNA was used for the first PCR amplification with WWOX-specific primers (forward primer, 5Ј-AGTTCCTGAGCGAGTGGACC-3Ј; reverse primer, 5Ј-TTACTTTCAAACAGGCCACCAC-3Ј) in a volume of 50 l containing 20 pmol of each primer, 2.5 mM MgCl 2 , 1.5 mM deoxynucleoside triphosphate mix, 1ϫ PCR buffer, and 2 units of AmpliTaq Gold (Perkin-Elmer). PCR cycles included one cycle at 95°C for 8 min followed by 30 cycles at 94°C for 30 s, 57°C for 30 s, and 72°C for 1 min, with a final extension step at 72°C for 5 min in a Perkin-Elmer Gene Amp PCR system 9600. One l of the first PCR amplification product was used for a second PCR amplification with WWOX-nested primers (forward primer, 5Ј-AGGTGCCTCCACAGTC-3Ј; reverse primer, 5Ј-GTGTGTGCCCATCCGCTCT-3Ј) under the same conditions as those of the first PCR. The amplified products were analyzed by electrophoresis on a 1.5% agarose gel. DNA bands corresponding to the normal-and abnormal-sized WWOX transcripts were excised from the gel, purified using the QIAquick gel extraction kit (Qiagen), and sequenced on the Applied Biosystems Prism 377 DNA sequencing system. Two primer sets were designed to amplify the entire open reading frame.
Methylation Analysis. Genomic DNA was treated with sodium bisulfite according to methods described previously (15) . Briefly, 1 g of the genomic DNA was denatured by 2 M NaOH, and then incubated in 3 M sodium bisulfite and 10 mM hydroquinone for 17 h at 55°C. Bisulfite-treated DNA was extracted using a genomic DNA clean-up kit (Promega, Madison, WI). Modified DNA was amplified using nested PCR that amplify the putative promoter region, including a CpG-rich area surrounding the translation start codon (11) . Primers for the nested PCR amplification were 5Ј-TAGTTTTTATTAT-TATTAGTTTTTATTATT-3Ј (forward primer) and 5Ј-ACT-CATCCTCACTATCCATATCAT-3Ј (reverse primer) for the first PCR, and 5Ј-AGTTTTTATTATTATGAGTTTTTATTA-AAT-3Ј (forward primer) and 5Ј-CCATATCATCCAAC-CCCACATA-3Ј (reverse primer) for the second PCR. PCR was performed in 50-l reaction volumes containing 1ϫ PCR buffer II (Perkin-Elmer, Branchburg, NJ), 2 mM MgCl 2 , 0.2 mM of each deoxynucleoside triphosphate, 10 pmol of each primer, 1 unit of AmpliTaq Gold polymerase (Perkin-Elmer), and 50 ng bisulfite-modified DNA. PCR cycling conditions were 10 min at 95°C, 35 cycles of a 30-s denaturation at 94°C, a 30-s annealing at 55°C, a 60-s extension at 72°C, and a final extension step of 5 min at 72°C. PCR products were subcloned into the pGEM-T Easy vector (Promega), and six clones were sequenced.
Real-Time Reverse Transcription PCR. Real-time reverse transcription PCR was performed using primers designed to span intron 6. The forward primer on exon 6 was 5Ј-CGTG-CAGCATTTTGCTGAAG-3Ј and the reverse primer on exon 7 was 5Ј-AGTTGCTGCGTTGCACACA-3Ј. The probe sequence 5Ј-AGGCCAAGAATGTGCCTCTTCATGTGC-3Ј was labeled with the reporter dye VIC. 6-Carboxytetramethylrhodamine was used as the quencher. ␤-Actin was used as an internal control. Thirty-five cycles were run with an annealing temperature of 62°C and an elongation time of 30 s. All of the reactions were performed in an ABI PRISM 7000 Sequence Detection System (Applied Biosystems). Each sample was performed in triplicate. After normalization of the samples with the respective ␤-actin control, a t test was used to compare the quantitation of WWOX expression. All of the analyses were performed with the Statistical Package for the Social Sciences for Windows (SPSS, Inc., Release 10.0.7, 2000). The t tests were considered statistically significant if P Ͻ 0.05.
5-Aza-2-Deoxycytidine (5-AZAC) Treatment. To determine whether treatment of a methylated cell line with a demethylating agent induced WWOX expression, we treated the pancreatic cancer cell line Hs766T with 5-AZAC. Cells were plated and incubated for 3 days with 1 M of 5-AZAC. The medium and the drug were replaced every 24 h. RNA obtained from wild-type and 5-AZAC-treated cells was used to make cDNA for real-time reverse transcription PCR analysis. Primers and probe spanning intron 8 were used as described elsewhere (11) . Analysis of data was performed as described previously.
Western Blot. Proteins were extracted from all 9 of the pancreatic cancer cell lines by lysing cells in a Triton extraction buffer containing 10 mM Tris-Hcl (pH7.4), 5 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml, and 1 mM sodium orthovanadate.
Concentration of proteins in the lysates was measured using the Bio-Rad protein assay reagent (Bio-Rad Inc., Richmond, CA) according to the manufacturer's protocol. Normal human pancreas tissue lysate was obtained from ProSci, Inc. (Poway, CA). Equal amounts of protein (20 g) were boiled in Laemmli sample buffer, separated in a 4 -20% SDS-PAGE gel (Ready Gels; Bio-Rad, Inc.), and transferred to nitrocellulose membranes (Bio-Rad, Inc.). Filters were blocked in Tris-buffered saline with 5% skim milk for 2 h. Primary antibody exposure was performed for 2 h at room temperature with mouse monoclonal anti-WWOX and anti-␤-actin (Amersham Biosciences) antibodies. Peroxidase-linked secondary goat antimouse IgG antibodies (Amersham Biosciences) and the enhanced chemiluminescence Western Blotting Detection kit (Amersham Biosciences) were used for detection. Monoclonal antibodies against the human WWOX protein were elicited (16) . Briefly, we generated a glutathione S-transferase/WWOX fusion protein containing the first 171 amino acids of the WWOX NH 2 terminus fused in frame to the glutathione S-transferase protein. The WWOX insert was obtained by reverse transcription-PCR from normal esophagus as described. The amplification was performed with 5Ј-GATGGCAGCGCTGCGCTACGCGGGG-3Ј as a forward primer and 5Ј-TCATCA TTCTTCTAAAAT-GCGTGACACTC-3Ј as a reverse primer. Subsequently, the amplified insert was subcloned into the SmaI restriction site of pGEX-2TK; the pGEX-2TK-WWOX plasmid then was sequenced to exclude random mutations in the insert. Clones producing the WWOX-specific antibodies were isolated by testing their supernatants on Western blot strips prepared with total proteins purified from either wild-type or pMV-WWOX transiently transfected HEK293 cells. WWOX monoclonal antibodies were used at 1:1000.
WWOX Transfection and Colony Assay. WWOX cDNA was cloned in sense orientation into pMV-7, a eukaryotic expression vector (17) . This vector has a neomycin gene that provides G-418 resistance for the selection of transfectants and a long terminal repeat promoter that controls the expression of the transgene. Lipofectamine (Invitrogen) was used to transfect AsPc1 and Panc1 cells with 5 g of empty vector and an equimolar quantity of pMV-7/WWOX according to the manufacturer's protocol. G-418 was added to the medium at a concentration of 400 g/ml. Colonies were stained with 500 g of crystal violet in 20% methanol and a colony count was performed. 
RESULTS
LOH and Mutation Analysis. We searched for LOH using four microsatellite markers within WWOX. The loci D16S3029, D16S3096, and D16S504 are located in intron 8, and D16S518 is located in exon 1 (13) . All 15 of the cases were informative for at least one of the loci examined, and in 4 cases (27%) we detected LOH (Table 1) . Representative results of LOH analysis are shown in Fig. 1A . To determine whether the WWOX gene was the target of functional inactivation in pancreatic adenocarcinoma, we screened for somatic mutations in the WWOX gene by direct sequencing of PCR products of all of the WWOX exons in tumor cells, in normal counterparts for each cancer, and in 9 human pancreatic cancer cell lines. In the Panc1 cancer cell line, exons 7 and 8 were not amplified, indicating a homozygous deletion. We confirmed this homozygous deletion of exons 7 and 8 in Panc1 by duplex PCR (data not shown). All of the exons were amplified in the other 8 cell lines and in 15 paired samples. No somatic point mutations were identified in the cell lines and clinical samples.
Methylation Analysis of the WWOX Gene Promoter Region. To evaluate the methylation status of the promoter region of WWOX in pancreatic adenocarcinoma, we used a sodium bisulfite sequence approach. Two of 9 pancreatic cell Table 1 ). The result of bisulfite sequence analysis of Hs766T is shown in Fig. 1B . In the PCR product from the specific primers for bisulfite-treated DNA, methylated cytosine appears as a G signal in the complementary strand at the CpG dinucleotide only at the Ϫ37 position. Other unmethylated cytosine nucleotides, including those in the CpG dinucleotides, changed to thymines because of bisulfite modification. This site-specific methylation of a single CpG site of Panc1 and Hs766T was detected in six of six and five of six clones, respectively. In primary tumors, case 1 showed methylation at cytosines Ϫ37, Ϫ43, and Ϫ53 in six of six clones. Case 5 showed methylation at all of the cytosines from Ϫ148 to Ϫ37 in six of six clones (Table 1) . transcripts, and Capan2 showed an aberrant band with a normal-sized transcript (Fig. 1C) . Sequence analysis of aberrant transcripts showed frameshifts in the open reading frame (Table 1) . Of 15 primary tumors, 1 case (case 6) showed an aberrant transcript plus a normal-sized WWOX reverse transcription-PCR product (Fig. 1D) , and sequence analysis of the aberrant transcript showed deletion of exons 2-8. In 1 case (case 2), no WWOX transcript was detected ( Table 1 ). The remaining primary tumors showed only a normal-sized transcript.
Real-Time Reverse Transcription-PCR Analysis. Fig.  2 summarizes the results of the comparison of WWOX expression in the 9 pancreatic cancer cell lines and in the normal pancreatic tissue control. Although Panc1 showed no expression of the WWOX gene, the remaining 8 cell lines showed a reduction in expression. Subsequently, we assessed the expression of WWOX in 15 primary pancreatic adenocarcinomas. Six cases (cases 2, 6, 9, 10, 13, and 14; 40%) showed a reduction in expression of WWOX.
Western Blot. Fig. 3 shows the results of a Western blot analysis of the pancreatic cancer cell lines. Although Panc1 showed no expression of WWOX, the other 8 cell lines showed a clear reduction in WWOX expression compared with normal pancreas tissue lysate. Fig. 4 A, colony assay demonstrating decreased colony formation after WWOX transfection. B, quantification of decreased colony formation by colony count; bars, ϮSD. 
